The DOI matches its Crossref record; 110 of the 112 references it cites were found in a registry or an index; 1 of the 72 sources its claims cite were checked for support.
“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Open accessAbstract
Conservative surgical treatment for symptomatic endometriosis is frequently associated with only partial relief of pelvic pain or its recurrence. Therefore, medical therapy constitutes an important alternative or complement to surgery. However, no available compound is cytoreductive, and suppression instead of elimination of implants is the only realistic objective of pharmacological intervention. Because this implies prolonged periods of treatments, only medications with a favourable safety/tolerability/efficacy/cost profile should be chosen. In the past few years, innumerable new drugs for endometriosis, which would interfere with several hypothesized pathogenic mechanisms, have been studied and their use foreseen. However, robust evidence of in vivo safety and efficacy is lacking and, at the moment, the principal modality to interfere with endometriosis metabolism is still hormonal manipulation. Regrettably, in spite of consistent demonstration of a major effect on pain even in patients with deeply infiltrating lesions, progestins are underestimated and dismissed in favour of more scientifically fashionable and up-to-the-minute alternatives. Moreover, oral contraceptives (OCs) dramatically reduce the rate of post-operative endometrioma recurrence and should now be considered an essential part of long-term therapeutic strategies in order to limit further damage to future fertility. Finally, women who have used OC for prolonged periods will be protected from an increased risk of endometriosis-associated ovarian cancer. To avoid the several subtle modalities for distorting facts and orientating opinions in favour of specific compounds, progestins and monophasic OC used continuously are here proposed as the reference comparator in all future randomized controlled trials on medical treatment for endometriosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that medical treatment for endometriosis should aim at long-term suppression rather than cure, and that progestins and continuous monophasic oral contraceptives (OCs) are effective, safe, inexpensive options that are underused. It proposes these as reference comparators in future randomized controlled trials and highlights postoperative OC use for preventing endometrioma and symptom recurrence.
Key findings
- No available drug is cytoreductive; suppression is the only realistic objective, so prolonged therapy is needed. In nine controlled trials identified from 1990–2010, progestins and OCs relieved pain and were generally not inferior to danazol, GnRH agonists, and aromatase inhibitors.
- Postoperative OC use dramatically reduced endometrioma recurrence in three controlled studies, with odds ratios from 0.04 (Takamura et al., 2009) to 0.32 (Seracchioli et al., 2010a). Two RCTs showed reduced dysmenorrhoea recurrence with postoperative progestin/OC versus expectant management (OR 0.14 and 0.32).
- Recurrence after conservative surgery is common: 10% at 1 year, 25% at 3 years, and 45% at 5 years (Evers et al., 1991); >20% at 2 years and 40–50% at 5 years (Guo, 2009); endometrioma recurrence reportedly 30–50% after 2–5 years.
- Costs are substantial: global endometriosis cost was $18.8–$22 billion per year based on 2002 US data; annual therapy costs ranged from €18 for low-dose norethisterone acetate to about €2100 for aromatase inhibitors or GnRH agonists, and about €4200 if combined.
Methods
- Narrative review/opinion article; no primary data. A MEDLINE search from January 1990 to July 2010 in English (MeSH terms: endometriosis, progestins, OCs, medical therapy) identified nine controlled trials comparing a progestin or OC with an alternative hormonal compound.
- A second MEDLINE search from January 2000 to July 2010 (MeSH terms: endometriosis, endometrioma, recurrence, OC, laparoscopy) identified three controlled studies on long-term postoperative OC use and endometrioma recurrence.
- The paper also cites RCTs on postoperative progestin/OC use for symptom recurrence; study quality was not assessed, and no meta-analysis was performed.
Limitations
- Stated: study quality was not assessed in the MEDLINE search; information on the cost of endometriosis to patients and society is limited.
- Evident: this is a narrative/opinion review with explicit advocacy for progestins and OCs, without systematic quality appraisal, risk-of-bias assessment, or meta-analysis; conclusions may be influenced by selected citation and interpretation of the literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
48 Not checked yet · 33 Own interpretation · 6 No basis given · 1 Partly supported · 1 Own method · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“whereas low-dose oral NETA is probably the best choice for rectovaginal lesions”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
What the sources say
- Partly supportedcites Vercellini et al., 2005 sourceExperimental — accuracy not yet measured
The Abstract calls low-dose norethindrone acetate an effective, tolerable, inexpensive first-choice medical alternative to repeat surgery for symptomatic rectovaginal lesions in patients who do not seek conception. The claim's broader “best choice for rectovaginal lesions” omits those limits and suggests a preference over all treatments that the paper does not establish. (LLM, conf=0.88)
- Not checked yetcites Vercellini et al., 2009d
- Not checked yetcites Remorgida et al., 2007a
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“women who have used OC for prolonged periods will be protected from an increased risk of endometriosis-associated ovarian cancer”
- Also stated in: § Life is now! · hedged
“women who have used OC for prolonged periods might be reassured that they will be protected from an increase in risk of endometriosis-associated ovarian cancer (Missmer et al., 2004)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
What the sources say
- Not checked yetcites Missmer et al., 2004 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Life is now! · hedged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“in spite of consistent demonstration of a major effect on pain even in patients with deeply infiltrating lesions, progestins are underestimated and dismissed in favour of more scientifically fashionable and up-to-the-minute alternatives”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, robust evidence of in vivo safety and efficacy is lacking and, at the moment, the principal modality to interfere with endometriosis metabolism is still hormonal manipulation.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“oral contraceptives (OCs) dramatically reduce the rate of post-operative endometrioma recurrence”
- Also stated in: § Prevention of recurrence? Yes we can! · boosted
“A dramatic reduction in the risk of reappearance of endometriotic cysts in OC users was consistently observed independent of cyclic or continuous use, with odds ratios varying from 0.04 (Takamura et al., 2009) to 0.32 (Seracchioli et al., 2010a).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
What the sources say
- Not checked yetcites Takamura et al., 2009
- Not checked yetcites Seracchioli et al., 2010a
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Prevention of recurrence? Yes we can! · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“A decreased PR-B/PR-A ratio has been demonstrated not only in ectopic tissue (Attia et al., 2000), but also in eutopic endometrium of women with endometriosis (Igarashi et al., 2005), albeit not consistently (Bukulmez et al., 2008).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Challenging conventional biologic wisdom
What the sources say
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“the induction of experimental disease in mice leads to a completely opposite hormonal receptor expression, as total endometrial PR and PR-B were shown to be increased, and PR-A decreased in animals with endometriosis”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Challenging conventional biologic wisdom
What the sources say
- Not checked yetcites Lee et al., 2009
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Numerous clinical studies and systematic reviews have consistently demonstrated that hormonal compounds with very dissimilar pharmacological profiles determine comparable pelvic pain reduction.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites American College of Obstetricians and Gynecologysts, 2000
- Not checked yetcites Kennedy et al., 2005
- Not checked yetcites Royal College of Obstetricians and Gynaecologysts, 2006
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“and, most importantly, with potentially severe side effects”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“several of the compounds included in Table I are associated with uncertain or no efficacy, such as pentoxifylline (Lv et al., 2009) or anti-TNF-a (Lv et al., 2010)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites Lv et al., 2009
- Not checked yetcites Lv et al., 2010
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 13
- The quote only partly states this claim. 1
- It may state two separate claims as one. 14
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, no available compound is cytoreductive, and suppression instead of elimination of implants is the only realistic objective of pharmacological intervention.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“generally well-tolerated”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
In the paper
“After treatment discontinuation, symptoms recurred without significant between-group differences, demonstrating that also aromatase inhibitors are neither cytoreductive nor curative.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
What the sources say
- Not checked yetcites Ferrero et al., 2009b
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Disease control may result in an acceptable improvement of quality of life, only if also safety, tolerability and costs of medications are taken into adequate account.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of major untoward effects may be acceptable in the above clinical context, but not in otherwise healthy women affected by a benign condition.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“there are also substantial economic implications if efficacy is overestimated and the medication over-utilized, given that usually new molecules are among the most costly drugs on the market”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Introduction
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: New molecules are usually among the most costly drugs on the market.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, again it is unclear if the increased expression of this cytochrome P-450 complex constitutes the very reason for survival and proliferation of regurgitated endometrial cells, or if it is the consequence of local inflammation”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moreover, during the reproductive period, aromatase inhibitors stimulate ovarian function, as they reduce the hypothalamic-pituitary estrogen feedback, with consequent rise in GnRH secretion, elevations in FSH and LH, and augmented follicular development.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Pharmacological extravagance
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“for the present the therapeutic target is not endometriosis cytoreduction, but suppression, which implies the survival of ectopic implants independently of the drug type, dosage, and duration of use (Evers, 1987)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > The unpalatable taste of medical therapies
What the sources say
- Not checked yetcites Evers, 1987 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: A compound with selective properties only against the ectopic endometrial cell has not yet been synthesized.
In the paper
“According to Evers et al. (1991), 10% of patients redeveloped signs and symptoms of endometriosis after a 1-year follow-up period, 25% after 3 years and 45% after 5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites Evers et al., 1991
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In both cases, subjective and metabolic untoward effects would considerably undermine safety and tolerability.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Study quality was not assessed.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In fact, prescribing medications for a few months has no clear rationale and exposes women to extenuating recurrences of symptoms and lesions and to the risk of repetitive surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Life is now!
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maintaining that progestins and OCs may be of a little value in the prevention of endometrioma recurrence and that the use of post-operative medications may cause unnecessary side effects and cost increase seems questionable in light of recent research findings.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“which is substantially higher than the estimated costs of other chronic disorders, such as Crohn's disease ($865 million) and migraine ($13-17 billion; Rogers et al., 2009).”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
What the sources say
- Not checked yetcites Rogers et al., 2009
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these medications are still addressed with scepticism and sometimes not even mentioned among effective therapeutic alternatives.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“Also DeCherney (1992) maintains that the endometriosis annual recurrence rate may be as high as 15% and that cumulative rates 40% after 3-5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites DeCherney, 1992
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“According to studies based on 2002 US data, the global cost of the disease (including analgesics, hormonal therapies, gynaecological consultations, hospital admissions, surgical procedures, days off-work and reduced productivity) varies between $18.8 and $22 billion per year (Gao et al., 2006;Simoens et al., 2007)”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, pain symptoms relapse exposes patients to repetitive suffering, frustration, multiple courses of medical therapy and risk of serial surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Recently, Guo (2009) calculated that the disease relapse rate is higher than 20% at 2 years and 40 -50% at 5 years.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Prevention of recurrence? Yes we can!
What the sources say
- Not checked yetcites Guo, 2009
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The latest pills are generally the most expensive, but not necessarily the most cost-effective.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Scientific glasnost
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Not all women using progestins will be relieved from pain, not all will be satisfied with their treatment, not all will continue it and not all will avoid surgery.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“as the mechanism of action seems to be ovulation inhibition.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“should be informed in an unbiased manner, as any misinformation may expose many of them to repeated surgery and a decrease in the probability of conception.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“But at least two-thirds of them could substantially ameliorate their health-related quality of life, controlling the disease with marginal associated morbidity.”
§ 'Waiting for Godot' † : a commonsense approach to the medical treatment of endometriosis > Conclusions
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
The paper relies on this without support.
Definitive surgery for endometriosis is generally not accepted by patients wishing to preserve fertility.
“an option generally not accepted by patients wishing to preserve fertility”
The paper relies on this without support.
Publication of reports in peer-reviewed journals is the most important source of information on novel drugs for physicians who generally have limited clinical experience with the latest treatments.
“publication of reports in 'peer-reviewed' journals constitutes the most important source of information on novel drugs for physicians who generally have limited clinical experience with the latest treatments”
The paper relies on this without support.
New molecules are usually among the most costly drugs on the market.
“usually new molecules are among the most costly drugs on the market”
The paper relies on this without support.
A compound with selective properties only against the ectopic endometrial cell has not yet been synthesized.
“As a compound with selective properties only against the ectopic endometrial cell has not yet been synthesized”
The paper relies on this without support.
Medical therapies for endometriosis are not curative.
“given that medical therapies for endometriosis are not curative”
The paper relies on this without support.
Medical treatment for endometriosis does not influence reproductive performance of infertile women.
“Medical treatment for endometriosis does not influence reproductive performance of infertile women.”
The paper relies on this without support.
Dropouts are usually largely dissatisfied because of persisting pain or development of major side effects.
“In fact, dropouts are usually largely dissatisfied because of persisting pain or development of major side effects.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, when hormonal treatments are to be continued for long periods, estrogen-progestins and progestins appear to be among the compounds that most favorably balance benefits, harms, and costs (30,31).”
From A stepped-care approach to symptomatic endometriosis management: A participatory research initiative (2018) · cites this paper as [31]
Citations
Cites
1 retracted
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Prentice, A., Deary, A., Goldbeck-Wood, S., Farquhar, C., & Smith, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000346 · Cited by 116 · cited 1×
“…in relieving pain, generally well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et…”
BackgroundRetractedGiudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924 · cited 1×
“Endometriosis is an estrogen-dependent chronic inflammatory disease (Giudice, 2010) that can be effectively cured by definitive surgery (Shakiba et al., 2008), an option generally not accepted by patients wishing to preserve fertility.”
BackgroundBulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 2×
“This is acknowledged in several guidelines on the treatment of endometriosis (American College of Obstetricians and Gynecologysts, 2000; Kennedy et al., 2005; Royal College of Obstetricians and Gynaecologysts, 2006; Practice Committee of the American Society for Reproductive Medicine, 2008; Society of Obstetricians an…”
BackgroundMethodRecurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719 · cited 3×
“This would explain why 9% of patients do not respond to progestin treatment (Guo, 2009). by guest on Septem ber 24, 2015 http://hum rep.oxfordjournals.org/ D ow nloaded from The expression of human progesterone receptor (PR) is controlled by two promoters that direct the synthesis of mRNA…”
BackgroundStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 2×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et al., 2010a).”
BackgroundPetta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363 · cited 1×
“…not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al.,…”
BackgroundEndometriosis: cost estimates and methodological perspective
Simoens, S., Hummelshoj, L., & D'Hooghe, T. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm010 · Cited by 357 · cited 2×
“8 and $22 billion per year (Gao et al., 2006; Simoens et al., 2007), which is substantially higher than the estimated costs of other chronic disorders,”
BackgroundInfluentialPriorities for Endometriosis Research: Recommendations From an International Consensus Workshop
Rogers, P. A. W., D’Hooghe, T. M., Fazleabas, A., Gargett, C. E., Giudice, L. C., Montgomery, G. W., Rombauts, L., Salamonsen, L. A., & Zondervan, K. T. (2009) · Reproductive Sciences · doi:10.1177/1933719108330568 · Cited by 346
Surgical Treatment of Endometriosis: A 7-Year Follow-up on the Requirement for Further Surgery
Shakiba, K., Bena, J. F., McGill, K. M., Minger, J., & Falcone, T. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181758ec6 · Cited by 339 · cited 3×
“(Giudice, 2010) that can be effectively cured by definitive surgery (Shakiba et al., 2008), an option generally not accepted by patients wishing to preserve fertility.”
BackgroundThe effect of surgery for symptomatic endometriosis: the other side of the story
Vercellini, P., Crosignani, P. G., Abbiati, A., Somigliana, E., Viganò, P., & Fedele, L. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn062 · Cited by 339 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationRising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328 · cited 3×
“Rising et al. (2008) demonstrated a major gap between information submitted to the Food and Drug Administration regarding new drug applications during the period 2001–2002, and information eventually reaching medical journals.”
BackgroundPromoter Hypermethylation of Progesterone Receptor Isoform B (PR-B) in Endometriosis
Wu, Y., Strawn, E., Basir, Z., Halverson, G., & Guo, S. (2006) · Epigenetics · doi:10.4161/epi.1.2.2766 · Cited by 323 · cited 1×
“The downregulation of PR-B expression as a consequence of the hypermethylation of the gene promoter region has also been observed by Wu et al. (2006) in epithelial cells of some ectopic foci.”
BackgroundVercellini, P., Trespidi, L., Colombo, A., Vendola, N., Marchini, M., & Crosignani, P. G. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56039-7 · Cited by 311 · cited 1×
“…progestins and OCs are effective in relieving pain, generally well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b;…”
BackgroundSelf-citationNonsteroidal anti-inflammatory drugs for pain in women with endometriosis
Brown, J., Crawford, T. J., Allen, C., Hopewell, S., & Prentice, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004753.pub4 · Cited by 308
Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells
Noble, L. S. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.2.600 · Cited by 301
The Fight against Disease Mongering: Generating Knowledge for Action
Moynihan, R. N., & Henry, D. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030191 · Cited by 293 · cited 3×
“Public money is wasted [. . .] in part as a result of drug companies promoting their products, through physicians, to people [. . .] for whom a powerful prescription may be unnecessary or even do more harm than good’ (Moynihan and Henry, 2006).”
BackgroundInfluentialVercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289 · cited 4×
“Progestins and OCs allow a practical combination of these aspects (Vercellini et al., 1997, 2003a; Davis et al., 2007).”
BackgroundInfluentialSelf-citationEconomic burden of endometriosis
Gao, X., Outley, J., Botteman, M., Spalding, J., Simon, J. A., & Pashos, C. L. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.06.015 · Cited by 289
Harada, T., Momoeda, M., Taketani, Y., Hoshiai, H., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.08.051 · Cited by 289 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundDlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundHarada, T., Momoeda, M., Taketani, Y., Asô, T., Fukunaga, M., Hagino, H., & Terakawa, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.080 · Cited by 277 · cited 1×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et al., 2010a).”
BackgroundVercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Self-citationPre and post-operative medical therapy for endometriosis surgery
Furness, S., Yap, C., Farquhar, C. M., & Cheong, Y. C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003678.pub2 · Cited by 257 · cited 1×
“Studies reporting the short-term (6 months) post-operative OC use were not considered (Muzi et al., 2000; Yap et al., 2004; Sesti et al., 2007).”
BackgroundProgestagens and anti-progestagens for pain associated with endometriosis
Brown, J., Kives, S., & Akhtar, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002122.pub2 · Cited by 250 · cited 1×
“…in relieving pain, generally well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et…”
BackgroundHormonal contraception and risk of cancer
Cibula, D., Gompel, A., Mueck, A. O., Vecchia, C. L., Hannaford, P. C., Skouby, S. O., Zikán, M., & Dušek, L. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq022 · Cited by 250 · cited 1×
“The extensive epidemiologic information available demonstrates that OCs and progestins are the safest medical alternative for long-term treatments of endometriosis (American College of Obstetricians and Gynecologysts, 2010; Cibula et al., 2010; Hannaford et al., 2010).”
BackgroundTelimaa, S., Puolakka, J., & Kauppila, A. (1987) · Gynecological Endocrinology · doi:10.3109/09513598709082692 · Cited by 241 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundHannaford, P. C., Iversen, L., Macfarlane, T. V., Elliott, A. M., Angus, V., & Lee, A. J. (2010) · BMJ · doi:10.1136/bmj.c927 · Cited by 240 · cited 1×
“The extensive epidemiologic information available demonstrates that OCs and progestins are the safest medical alternative for long-term treatments of endometriosis (American College of Obstetricians and Gynecologysts, 2010; Cibula et al., 2010; Hannaford et al., 2010).”
BackgroundAdvances in the management of endometriosis: an update for clinicians
Crosignani, P., Olive, D., Bergqvist, A., & Luciano, A. (2006) · Human Reproduction Update · doi:10.1093/humupd/dmi049 · Cited by 237 · cited 3×
“…the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008; Ferrero et al., 2010a) and…”
BackgroundSelf-citationReproductive History and Endometriosis Among Premenopausal Women
Missmer, S. A., Hankinson, S. E., Spiegelman, D., Barbieri, R. L., Malspeis, S., Willett, W. C., & Hunter, D. J. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000142714.54857.f8 · Cited by 237 · cited 2×
“Finally, women who have used OC for prolonged periods might be reassured that they will be protected from an increase in risk of endometriosis-associated ovarian cancer (Missmer et al., 2004).”
BackgroundAilawadi, R., Jobanputra, S., Kataria, M., Gürateş, B., & Bulun, S. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.09.029 · Cited by 233 · cited 2×
“…in premenopausal women, these compounds must be used together with other drugs [e.g. GnRH agonists, danazol, oral contraceptives (OCs), progestins] that could effectively suppress gonadotrophins and reduce ovarian activity (Soysal et al., 2004; Ailawadi et al., 2005; Amsterdam et al., 2005).”
BackgroundProgestins for symptomatic endometriosis: a critical analysis of the evidence
Vercellini, P., Cortesi, I., & Crosignani, P. G. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00193-3 · Cited by 229 · cited 1×
“Progestins and OCs allow a practical combination of these aspects (Vercellini et al., 1997, 2003a; Davis et al., 2007).”
BackgroundSelf-citationStrowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 2×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et al., 2010a).”
BackgroundSoysal, S. (2004) · Human Reproduction · doi:10.1093/humrep/deh035 · Cited by 227 · cited 3×
“…in premenopausal women, these compounds must be used together with other drugs [e.g. GnRH agonists, danazol, oral contraceptives (OCs), progestins] that could effectively suppress gonadotrophins and reduce ovarian activity (Soysal et al., 2004; Ailawadi et al., 2005; Amsterdam et al., 2005).”
BackgroundSeracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Montanari, G., Keramyda, A., & Venturoli, S. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.052 · Cited by 224 · cited 6×
“OR 95% CI Vercellini et al. (2003c) 40 LNG-IUD 12 2/20 (10) 9/20 (45) 0.14 0.02–0.75 Seracchioli et al. (2010b) 311 Continuous/cyclic OC 18 33/187a,b (18) 35/87 (40) 0.32 0.18–0.56 aCyclic and continuous OC users are considered together. bOnly subjects who completed the study are considered. by…”
BackgroundInfluentialAnastrazole and oral contraceptives: a novel treatment for endometriosis
Amsterdam, L. L., Gentry, W. L., Jobanputra, S., Wolf, M., Rubin, S. D., & Bulun, S. E. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.02.018 · Cited by 217 · cited 2×
“…in premenopausal women, these compounds must be used together with other drugs [e.g. GnRH agonists, danazol, oral contraceptives (OCs), progestins] that could effectively suppress gonadotrophins and reduce ovarian activity (Soysal et al., 2004; Ailawadi et al., 2005; Amsterdam et al., 2005).”
BackgroundPublication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
Lee, K., Bacchetti, P., & Sim, I. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050191 · Cited by 215 · cited 1×
“One of the methods to sway the evidence could be selecting the outcome in relation to the ‘experimental’ compound being investigated (Lee et al., 2008).”
MethodDanazol for pelvic pain associated with endometriosis
Farquhar, C., Prentice, A., Singla, A. A., & Selak, V. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000068.pub2 · Cited by 210 · cited 1×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et al., 2010a).”
BackgroundPractice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives
(2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181cb50b5 · Cited by 208
Lee, B., Du, H., & Taylor, H. S. (2009) · Biology of Reproduction · doi:10.1095/biolreprod.108.070391 · Cited by 204 · cited 2×
“…endometrial PR and PR-B were shown to be increased, and PR-A decreased in animals with endometriosis, thereby supporting not only the idea that alterations are secondary to disease establishment, but also that PR levels are highly susceptible to local and variable conditions (Lee et al., 2009).”
BackgroundRecurrence of ovarian endometrioma after laparoscopic excision
Koga, K., Takemura, Y., Osuga, Y., Yoshino, O., Hirota, Y., Hirata, T., Morimoto, C., Harada, M., Yano, T., & Taketani, Y. (2006) · Human Reproduction · doi:10.1093/humrep/del125 · Cited by 203 · cited 1×
“In particular, data are accumulating on the post-operative endometrioma recurrence rates, which reportedly vary between 30 and 50% after 2–5-year follow-up (Kikuchi et al., 2006; Koga et al., 2006; Vercellini et al., 2008b).”
BackgroundVercellini, P., Pietropaolo, G., De Giorgi, O., Pasin, R., Chiodini, A., & Crosignani, P. G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.03.083 · Cited by 197 · cited 1×
“…may constitute an adequate first-line option for peritoneal and ovarian endometriosis (Vercellini et al., 2003b, 2008a, 2009c), whereas low-dose oral NETA is probably the best choice for rectovaginal lesions (Vercellini et al., 2005, 2009d; Remorgida et al., 2007a; Ferrero et al., 2009b, 2010b,c).”
BackgroundSelf-citationPostoperative oral contraceptive exposure and risk of endometrioma recurrence
Vercellini, P., Somigliana, E., Daguati, R., Vigano, P., Meroni, F., & Crosignani, P. G. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.11.010 · Cited by 196 · cited 6×
“OR 95% CI Vercellini et al. (2008b) Cohort 277 28 9/102a (9) 26/46 (56) 0.07 0.03–0.18 Takamura et al. (2009) Cohort 87 24 1/34a (3) 17/39 (44) 0.04 0.00–0.32 Seracchioli et al. (2010a) RCT 239 24 17/148b (11) 20/69 (29) 0.32 0.15–0.66 EM, expectant management; OR, odds ratio; CI, confidence…”
BackgroundInfluentialSelf-citationProgesterone Receptor Isoform A But Not B Is Expressed in Endometriosis1
Attia, G. R., Zeitoun, K., Edwards, D., Johns, A., Carr, B. R., & Bulun, S. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6739 · Cited by 193
Inflammatory Status Influences Aromatase and Steroid Receptor Expression in Endometriosis
Bukulmez, O., Hardy, D. B., Carr, B. R., Word, R. A., & Mendelson, C. R. (2008) · Endocrinology · doi:10.1210/en.2007-0665 · Cited by 186 · cited 2×
“, 2005), albeit not consistently (Bukulmez et al., 2008).”
BackgroundAromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184 · cited 4×
“…to the many comprehensive reviews published on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo,…”
BackgroundInfluentialEndometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationCrosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei290 · Cited by 179
Self-citationExtracts from "Clinical Evidence": Endometriosis
Farquhar, C. M. (2000) · BMJ · doi:10.1136/bmj.320.7247.1449 · Cited by 176 · cited 1×
“In fact, it has been properly considered that ‘patient oriented outcomes [. . .] make a difference to the daily lives of women with endometriosis’ (Farquhar, 2000).”
Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1315 · Cited by 168 · cited 1×
“…GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009; Ferrero et al., 2009b; Strowitzki et…”
BackgroundIgarashi, T. M., Bruner-Tran, K. L., Yeaman, G. R., Lessey, B. A., Edwards, D. P., Eisenberg, E., & Osteen, K. G. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.01.113 · Cited by 163 · cited 2×
“A decreased PR-B/PR-A ratio has been demonstrated not only in ectopic tissue (Attia et al., 2000), but also in eutopic endometrium of women with endometriosis (Igarashi et al., 2005), albeit not consistently (Bukulmez et al., 2008).”
BackgroundVercellini, P., De Giorgi, O., Oldani, S., Cortesi, I., Panazza, S., & Crosignani, P. G. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70152-7 · Cited by 161 · cited 1×
“…progestins and OCs are effective in relieving pain, generally well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b;…”
BackgroundSelf-citationSeracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Savelli, L., & Venturoli, S. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.03.083 · Cited by 158 · cited 6×
“OR 95% CI Vercellini et al. (2003c) 40 LNG-IUD 12 2/20 (10) 9/20 (45) 0.14 0.02–0.75 Seracchioli et al. (2010b) 311 Continuous/cyclic OC 18 33/187a,b (18) 35/87 (40) 0.32 0.18–0.56 aCyclic and continuous OC users are considered together. bOnly subjects who completed the study are considered. by…”
BackgroundInfluentialSeracchioli, R., Mabrouk, M., Manuzzi, L., Vicenzi, C., Frasca, C., Elmakky, A., & Venturoli, S. (2009) · Human Reproduction · doi:10.1093/humrep/dep259 · Cited by 158 · cited 4×
“Thus, the solution to avoid repetitive short-term medical treatments and multiple laparoscopies appears already at hand (Seracchioli et al., 2009), and women not seeking Medical treatment of endometriosis 7”
BackgroundInfluentialCosson, M., Querleu, D., Donnez, J., Madelenat, P., Konincks, P., Audebert, A., & Manhes, H. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)03270-8 · Cited by 153 · cited 1×
“…well-tolerated, and not inferior to danazol, GnRH agonists and aromatase inhibitors (Vercellini et al., 1993, 1996; Prentice et al., 2000, 2004; Cosson et al., 2002; Petta et al., 2005; Schlaff et al., 2006; Crosignani et al., 2006b; Davis et al., 2007; Selak et al., 2007; Harada et al., 2009;…”
BackgroundProgestogens for endometriosis: forward to the past
Vercellini, P. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg030 · Cited by 147 · cited 4×
“Progestins and OCs allow a practical combination of these aspects (Vercellini et al., 1997, 2003a; Davis et al., 2007).”
BackgroundInfluentialSelf-citationFerrero, S., Camerini, G., Seracchioli, R., Ragni, N., Venturini, P., & Remorgida, V. (2009) · Human Reproduction · doi:10.1093/humrep/dep302 · Cited by 145 · cited 6×
“This finding has prompted performance of several pilot studies in women with endometriosis using one of the two available reversible aromatase inhibitors (i.e. anastrozole and letrozole), which compete with androgens for aromatase-binding sites (Patwardhan et al., 2008; Ferrero et al., 2009a).”
BackgroundInfluentialBias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results
Chan, A.-W. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050230 · Cited by 144 · cited 1×
“Scientific facts may be distorted and opinions manipulated not only by limiting publication of clinical-trial results (Rising et al., 2008; Guo et al., 2009), but also through other, probably more subtle and potentially even more dangerous, modalities (Chan, 2008).”
BackgroundMedical treatment for rectovaginal endometriosis: what is the evidence?
Vercellini, P., Crosignani, P. G., Somigliana, E., Berlanda, N., Barbara, G., & Fedele, L. (2009) · Human Reproduction · doi:10.1093/humrep/dep231 · Cited by 144 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationEndometriosis: current and future medical therapies
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Daguati, R., & Crosignani, P. G. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.10.001 · Cited by 136 · cited 6×
“OR 95% CI Vercellini et al. (2008b) Cohort 277 28 9/102a (9) 26/46 (56) 0.07 0.03–0.18 Takamura et al. (2009) Cohort 87 24 1/34a (3) 17/39 (44) 0.04 0.00–0.32 Seracchioli et al. (2010a) RCT 239 24 17/148b (11) 20/69 (29) 0.32 0.15–0.66 EM, expectant management; OR, odds ratio; CI, confidence…”
BackgroundInfluentialSelf-citationInflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation
Bäckdahl, L., Bushell, A., & Beck, S. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.023 · Cited by 135 · cited 2×
“Chemical transformations of DNA methylation contributes to disruption of the epigenetic code, which could result in a disturbed readout by the methylation-binding proteins involved in both activating and silencing of genes (Bäckdahl et al., 2009).”
BackgroundMuzii, L., Marana, R., Caruana, P., Catalano, G. F., Margutti, F., & Panici, P. B. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.106817 · Cited by 131
Telimaa, S., & Kauppila, A. (1987) · Gynecological Endocrinology · doi:10.3109/09513598709082709 · Cited by 127 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundIncreased Production of 17β-Estradiol in Endometriosis Lesions Is the Result of Impaired Metabolism
Delvoux, B., Groothuis, P. G., D’Hooghe, T. M., Kyama, C. M., Dunselman, G. A. J., & Romano, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2218 · Cited by 123 · cited 1×
“Finally, the implication of ectopic aromatase production in the development of endometriosis has recently been questioned and should be further elucidated (Colette et al., 2009; Colette and Donnez, 2009; Delvoux et al., 2009).”
BackgroundVercellini, P., Somigliana, E., Viganò, P., Matteis, S. D., Barbàra, G., & Fedele, L. (2010) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2010.04.018 · Cited by 121 · cited 3×
“Numerous uncontrolled studies indicate that post-operative OC exposure is associated with a major reduction in the risk of endometrioma recurrence (Seracchioli et al., 2009; Vercellini et al., 2010).”
BackgroundSelf-citationRepetitive surgery for recurrent symptomatic endometriosis: What to do?
Vercellini, P., Barbàra, G., Abbiati, A., Somigliana, E., Viganò, P., & Fedele, L. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.05.007 · Cited by 121 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationEvers, J. L. H. (1987) · Fertility and Sterility · doi:10.1016/s0015-0282(16)59062-1 · Cited by 118 · cited 1×
“…properties only against the ectopic endometrial cell has not yet been synthesized, for the present the therapeutic target is not endometriosis cytoreduction, but suppression, which implies the survival of ectopic implants independently of the drug type, dosage, and duration of use (Evers, 1987).”
BackgroundSystematic review of the effects of aromatase inhibitors on pain associated with endometriosis
Patwardhan, S., Nawathe, A., Yates, D., Harrison, G., & Khan, K. (2008) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01740.x · Cited by 116 · cited 2×
“This finding has prompted performance of several pilot studies in women with endometriosis using one of the two available reversible aromatase inhibitors (i.e. anastrozole and letrozole), which compete with androgens for aromatase-binding sites (Patwardhan et al., 2008; Ferrero et al., 2009a).”
BackgroundRecurrence rate of endometriomas following a laparoscopic cystectomy
Kikuchi, I., Takeuchi, H., Kitade, M., Shimanuki, H., Kumakiri, J., & Kinoshita, K. (2006) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340600627154 · Cited by 116
‘Blood On The Tracks’ from corpora lutea to endometriomas*
Vercellini, P., Somigliana, E., Vigano, P., Abbiati, A., Barbara, G., & Fedele, L. (2009) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.02055.x · Cited by 114 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationNorethisterone acetate in the treatment of colorectal endometriosis: a pilot study
Ferrero, S., Camerini, G., Ragni, N., Venturini, P. L., Biscaldi, E., & Remorgida, V. (2010) · Human Reproduction · doi:10.1093/humrep/dep361 · Cited by 107
Gray, S. G., & Dangond, F. (2006) · Epigenetics · doi:10.4161/epi.1.2.2678 · Cited by 101
Effects of Triptorelin Versus Placebo on the Symptoms of Endometriosis
Bergqvist, A., Bergh, T., Hogström, L., Mattsson, S., Nordenskjöld, F., & Rasmussen, C. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00019-3 · Cited by 99 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundTakamura, M., Koga, K., Osuga, Y., Takemura, Y., Hamasaki, K., Hirota, Y., Yoshino, O., & Taketani, Y. (2009) · Human Reproduction · doi:10.1093/humrep/dep297 · Cited by 98 · cited 5×
“As an example, implementation of a tertiary prevention strategy with OCs or progestins after surgery is associated with a decrease in symptoms and lesions recurrence (Vercellini et al., 2008b, 2010; Seracchioli et al., 2009, 2010a,b; Takamura et al., 2009), with a potential major impact on the above cost indicators.”
BackgroundMethodInfluentialSesti, F., Pietropolli, A., Capozzolo, T., Broccoli, P., Pierangeli, S., Bollea, M. R., & Piccione, E. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.01.053 · Cited by 97 · cited 1×
“Studies reporting the short-term (6 months) post-operative OC use were not considered (Muzi et al., 2000; Yap et al., 2004; Sesti et al., 2007).”
BackgroundChocolate cysts from ovarian follicles
Jain, S., & Dalton, M. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00367-2 · Cited by 94 · cited 1×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundAnti-TNF-α treatment for pelvic pain associated with endometriosis
Lu, D., Song, H., & Shi, G. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008088.pub3 · Cited by 91 · cited 2×
“…several of the compounds included in Table I are associated with uncertain or no efficacy, such as pentoxifylline (Lv et al., 2009) or anti-TNF-a (Lv et al., 2010) by guest on Septem ber 24, 2015 http://hum rep.oxfordjournals.org/ D ow nloaded from and, most importantly, with potentially severe…”
BackgroundVercellini, P., Somigliana, E., Viganò, P., Matteis, S. D., Barbàra, G., & Fedele, L. (2009) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1080/00016340903214973 · Cited by 91 · cited 8×
“In fact, ovulation seems crucial in the development of ovarian endometriotic cysts (Jain and Dalton, 1999; Vercellini et al., 2009f), and its suppression should substantially decrease the likelihood of cyst reappearance after laparoscopic treatment.”
BackgroundInfluentialSelf-citationNew medical treatments for endometriosis
Olive, D. L., Lindheim, S. R., & Pritts, E. A. (2004) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2004.03.005 · Cited by 86 · cited 3×
“…many experts published reviews on forthcoming medications for the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007;…”
BackgroundAbsence of aromatase protein and mRNA expression in endometriosis
Colette, S., Lousse, J. C., Defrère, S., Curaba, M., Heilier, J.-F., Langendonckt, A. V., Mestdagt, M., Foidart, J. M., Loumaye, E., & Donnez, J. (2009) · Human Reproduction · doi:10.1093/humrep/dep199 · Cited by 86 · cited 1×
“Finally, the implication of ectopic aromatase production in the development of endometriosis has recently been questioned and should be further elucidated (Colette et al., 2009; Colette and Donnez, 2009; Delvoux et al., 2009).”
BackgroundLetrozole and desogestrel‐only contraceptive pill for the treatment of stage IV endometriosis
REMORGIDA, V., ABBAMONTE, L. H., RAGNI, N., FULCHERI, E., & FERRERO, S. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00722.x · Cited by 83 · cited 4×
“Clearly, when these combined regimens are used for endometriosis, it is impossible to assess how much of the effect on pain is related to which of the two medications (Remorgida et al., 2007a).”
BackgroundInfluentialLetrozole and norethisterone acetate in colorectal endometriosis
Ferrero, S., Camerini, G., Ragni, N., Venturini, P. L., Biscaldi, E., Seracchioli, R., & Remorgida, V. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.02.023 · Cited by 80 · cited 3×
“…2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008; Ferrero et al., 2010a) and concluded that we were entering a new therapeutic era when several compounds would become available which could act on…”
BackgroundFedele, L., Bianchi, S., Bocciolone, L., Di Nola, G., & Franchi, D. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55792-6 · Cited by 74 · cited 1×
“However, six RCTs have already demonstrated that various treatments used for the relief of pain in women with symptomatic endometriosis are far superior to placebo (Telimaa et al., 1987; Dlugi et al., 1990; Fedele et al., 1993; Bergqvist et al., 1998; Harada et al., 2008; Strowitzki et al., 2010b).”
BackgroundSelf-citationEmerging drugs for endometriosis
Fedele, L., & Berlanda, N. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.167 · Cited by 73 · cited 4×
“In the past few years, many experts published reviews on forthcoming medications for the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and…”
BackgroundInfluentialSelf-citationMedical management of endometriosis
Peckham, B. M. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)80034-x · Cited by 73
Letrozole and norethisterone acetate in rectovaginal endometriosis
Remorgida, V., Abbamonte, L. H., Ragni, N., Fulcheri, E., & Ferrero, S. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.12.027 · Cited by 72 · cited 4×
“Clearly, when these combined regimens are used for endometriosis, it is impossible to assess how much of the effect on pain is related to which of the two medications (Remorgida et al., 2007a).”
BackgroundInfluentialDynamics and significance of placebo response in primary dysmenorrhea
Fedele, L., Marchini, M., Acaia, B., Garagiola, U., & Tiengo, M. (1989) · Pain · doi:10.1016/0304-3959(89)90110-3 · Cited by 66 · cited 1×
“Alternatively, if the antalgic properties of a drug are to be shown, what better than a placebo-controlled study, given that the placebo-effect is short-lived in this clinical condition (Fedele et al., 1989).”
BackgroundSelf-citationPharmacological Treatment of Endometriosis
Ferrero, S., Venturini, P. L., Ragni, N., Camerini, G. B., & Remorgida, V. (2009) · Drugs · doi:10.2165/00003495-200969080-00001 · Cited by 64
Current pharmacotherapy for endometriosis
Ferrero, S., Remorgida, V., & Venturini, P. L. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003685880 · Cited by 60 · cited 3×
“…2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008; Ferrero et al., 2010a) and concluded that we were entering a new therapeutic era when several compounds would become available which could act on…”
BackgroundEndometriosis: The way forward
Hompes, P. G. A., & Mijatovic, V. (2007) · Gynecological Endocrinology · doi:10.1080/09513590601010474 · Cited by 55 · cited 3×
“…2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008; Ferrero et al., 2010a) and concluded that we were entering a new…”
BackgroundA call for more transparency of registered clinical trials on endometriosis
Guo, S., Hummelshøj, L., Olive, D. L., Bulun, S. E., D’Hooghe, T. M., & Evers, J. L. H. (2009) · Human Reproduction · doi:10.1093/humrep/dep045 · Cited by 50 · cited 5×
“limiting publication of clinical-trial results (Rising et al., 2008; Guo et al., 2009), but also through other, probably more subtle and potentially”
BackgroundInfluentialLetrozole versus clomiphene citrate: which is better for ovulation induction?
Casper, R. F. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.03.094 · Cited by 45 · cited 1×
“Indeed, aromatase inhibitors have been suggested to correct ovulatory dysfunction as well as to increase the number of follicles in controlled ovarian stimulation protocols (Casper, 2009).”
BackgroundEstrogen and progesterone receptors in smooth muscle component of deep infiltrating endometriosis
Noël, J.-C., Chapron, C., Bucella, D., Buxant, F., Peny, M.-O., Fayt, I., Borghese, B., & Anaf, V. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.12.114 · Cited by 41 · cited 2×
“endometrium, and the receptor pattern and the biologic behaviour of the two mucosae are substantially similar (Noel et al., 2010).”
BackgroundD’Hooghe, T. M. (2003) · PubMed · doi:10.1097/01.gco.0000072859.73466.e3 · Cited by 40 · cited 4×
“In the past few years, many experts published reviews on forthcoming medications for the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and…”
BackgroundInfluentialDylan, B. (1998) · Duke University Press eBooks · doi:10.2307/j.ctv111jj7w.9 · Cited by 40
D’Hooghe, T. M. (2003) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/00001703-200306000-00006 · Cited by 40
Emerging drugs in endometriosis
Mihalyi, A., Simsa, P., Kyama, C. M., Meuleman, C., Mwenda, J. M., & D’Hooghe, T. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.3.503 · Cited by 38
Nothnick, W. B., & D’Hooghe, T. M. (2003) · Gynecologic and Obstetric Investigation · doi:10.1159/000072073 · Cited by 37 · cited 2×
“…and the main results observed in the various studies, reference is made to the many comprehensive reviews published on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a;…”
BackgroundIs there a solution for recurrent endometriosis?
Evers, J. L. H., Dunselman, G. A., Land, J. A., et al. (1991) · PubMed · Cited by 36
New drugs in development for the treatment of endometriosis
Fedele, L., Somigliana, E., Frontino, G., Benaglia, L., & Vigano, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1187 · Cited by 30 · cited 3×
“…2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008; Ferrero et al., 2010a) and concluded that we were entering a new therapeutic era when several…”
BackgroundSelf-citationAdvances in the medical management of endometriosis
Panay, N. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01739.x · Cited by 28 · cited 3×
“…on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay 2008; Ferrero et al., 2010a).”
BackgroundCytoskeletal responsiveness to progestins is dependent on progesterone receptor A levels
McGowan, E. M., Weinberger, R. P., Graham, J. D., et al. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310241 · Cited by 28 · cited 1×
“In breast and endometrial cancers, such alterations in the PR-A/PR-B ratio induced a marked effect on cell morphology, a consistent loss of adherent properties and features of invasive behaviour (McGowan et al., 2003).”
BackgroundNoncontraceptive Uses of Hormonal Contraception
King, J. (2011) · Journal of Midwifery & Women s Health · doi:10.1111/j.1542-2011.2011.00118.x · Cited by 26
Emerging drugs for endometriosis
Guo, S. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802548360 · Cited by 25 · cited 3×
“…on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay 2008; Ferrero et al., 2010a).”
BackgroundRobinson, D. R. (1991) · Current Opinion in Rheumatology · doi:10.1097/00002281-199106000-00001 · Cited by 25
Endometriosis: recurrence and retreatment.
DeCherney, A. H. (1993) · PubMed · Cited by 24
Pentoxifylline versus medical therapies for subfertile women with endometriosis
Lu, D., Song, H., Li, Y., Clarke, J., & Shi, G. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007677.pub2 · Cited by 19 · cited 2×
“such as pentoxifylline (Lv et al., 2009) or anti-TNF-a (Lv et al.”
BackgroundColette, S., & Donnez, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090328 · Cited by 16
ACOG Committee Opinion No. 412: Aromatase Inhibitors in Gynecologic Practice
(2008) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e318183fbd5 · Cited by 9
Investigational drugs for endometriosis
Chlouber, R. O., Olive, D. L., & Pritts, E. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.4.399 · Cited by 8 · cited 3×
“…medications for the disease (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay, 2008;…”
Background
Research works printed but not linked: 18
- 2006, Cochrane database of systematic reviews (Online), 18, CD005072
- 2005, Fertility and sterility, 81, 290
- 2008, MIDDLE EAST FERTIL SOC J, 13, 304
- 2009, Cochrane database of systematic reviews (Online), 15, CD004753
- 2008, 11, 1533
- 2007, Cochrane database of systematic reviews (Online), 18, CD001019
- 1991, The British journal of clinical practice, 45, 45
- 2009, Cochrane database of systematic reviews (Online), 8, CD007677
- 2010, Cochrane database of systematic reviews (Online), 17, CD008088
- 2003, Journal of Molecular Endocrinology, 2, 241
- 2008, Fertility and sterility, 90, S260
- 2000, Cochrane database of systematic reviews (Online), 2, CD002122
- 2004, Cochrane database of systematic reviews (Online), 2, CD000346
- 2008, 11, 1561
- 2007, Cochrane database of systematic reviews (Online), 17, CD000068
- 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obst trique et gyn cologie du Canada : JOGC, 32, S1
- 2008, American journal of obstetrics and gynecology, 198, 504
- 2004, Cochrane database of systematic reviews (Online), 3, CD003678
Cited by
Sorted by citations
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Self-citationConsensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Self-citationProgesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Clinical Management of Endometriosis
Falcone, T., & Lebovic, D. I. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31822adfd1 · Cited by 264
Estrogen-progestins and progestins for the management of endometriosis
Vercellini, P., Buggio, L., Berlanda, N., Barbara, G., Somigliana, E., & Bosari, S. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.10.022 · Cited by 243
Self-citation
Metadata
- Authors
- Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Vercellini, P.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-11
- Volume
- 26
- Issue
- 1
- Pages
- 3-13
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2117571760
- Semantic Scholar
- 63311710c2bb2995a9c0e275757690da0a84e5e1
- Cited by
- 180
- References
- 112
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 8 · 2018: 15 · 2017: 16 · 2016: 13 · 2015: 18 · 2014: 9 · 2013: 25 · 2012: 18
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Human Reproduction (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, progestins, oral contraceptives, hormonal manipulation, endometrioma recurrence, postoperative recurrence, endometriosis-associated ovarian cancer, deep infiltrating endometriosis, pelvic pain, drug safety and tolerability
- MeSH terms
- Contraceptives, Oral, Endometriosis, Female, Humans, Drugs, Investigational, Randomized Controlled Trials as Topic, Secondary Prevention, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
